Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
Number of UK clinical trials in decline since Brexit voteOngoing uncertainty and concern about Brexit has already cut the number of clinical trials carried out in the Share XNumber of UK clinical trials in decline since Brexit votehttps://pharmaphorum.com/news/number-of-uk-clinical-trials-in-decline-since-brexit-vote/
EU regulators review Janssen’s esketamine nasal spray antidepressantAn application for Janssen’s investigative nasal ketamine-based antidepressant is under review in Europe. Janssen, which is Johnson & Share XEU regulators review Janssen’s esketamine nasal spray antidepressanthttps://pharmaphorum.com/news/eu-regulators-review-janssens-esketamine-nasal-spray-antidepressant/
Novartis drug cuts serious complications in sickle cell diseaseNovartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can Share XNovartis drug cuts serious complications in sickle cell diseasehttps://pharmaphorum.com/news/novartis-drug-cuts-serious-complications-in-sickle-cell-disease/
UK biotech Orchard plans $172.5m US IPO to fund rare disease R&DUK biotech Orchard Therapeutics is planning a US IPO to expand use of its Strimvelis gene therapy, and Share XUK biotech Orchard plans $172.5m US IPO to fund rare disease R&Dhttps://pharmaphorum.com/news/uk-biotech-orchard-plans-172-5m-us-ipo-to-fund-rare-disease-rd/
Janssen and Arrowhead strike $3.7bn RNAi dealJanssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B Share XJanssen and Arrowhead strike $3.7bn RNAi dealhttps://pharmaphorum.com/news/janssen-and-arrowhead-strike-3-7bn-rnai-deal/
AZ’s old R&D site at heart of multimillion pound science property ventureAstraZeneca’s new R&D headquarters in Cambridge may be having teething problems – but ironically the site at Alderley Share XAZ’s old R&D site at heart of multimillion pound science property venturehttps://pharmaphorum.com/news/alderley-park-at-heart-of-multimillion-pound-science-property-venture/
Trial shows Roche’s new flu drug helps reduce symptoms in at-risk patientsBaloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief Share XTrial shows Roche’s new flu drug helps reduce symptoms in at-risk patientshttps://pharmaphorum.com/news/trial-shows-roches-new-flu-drug-helps-reduce-symptoms-in-at-risk-patients/
Humira developer Winter among Nobel chemistry prize winnersA scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, Share XHumira developer Winter among Nobel chemistry prize winnershttps://pharmaphorum.com/news/humira-developer-winter-among-nobel-chemistry-prize-winners/
